Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2024
Title: Hernán González-King: Innovator in Cardiotoxicity Prediction
Introduction
Hernán González-King is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach has the potential to improve patient outcomes and enhance treatment safety.
Latest Patents
Hernán González-King holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting the risk of cardiotoxicity based on the expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also identifies this set of miRNAs as biomarkers for predicting cardiotoxicity risk in patients receiving anthracyclines chemotherapy. Furthermore, it contemplates a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.
Career Highlights
Throughout his career, Hernán González-King has worked with esteemed institutions such as Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana and Maastricht University. His work has focused on advancing medical research and improving treatment methodologies for cancer patients.
Collaborations
Hernán has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have contributed to the development and refinement of his innovative research.
Conclusion
Hernán González-King is a pioneering inventor whose work in predicting cardiotoxicity risk represents a significant advancement in cancer treatment. His contributions have the potential to enhance patient safety and improve therapeutic outcomes.